Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $40
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and raises the price target from $28 to $40.
Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and raises the price target from $28 to $40.